| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6194943 | American Journal of Ophthalmology | 2016 | 16 Pages |
Abstract
Endophthalmitis following intravitreal bevacizumab, ranibizumab, and aflibercept injection appears to occur at similar rates and have comparable visual outcomes. This study suggests that the choice of anti-VEGF agent should be primarily based on efficacy and patient response rather than concern for risk of infection.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Nadim Rayess, Ehsan Rahimy, Philip Storey, Chirag P. Shah, Jeremy D. Wolfe, Eric Chen, Francis Char DeCroos, Sunir J. Garg, Jason Hsu,